Co-mutational status and PD-L1 expression in <i>KRAS</i> mutant non-small cell lung cancer (NSCLC): Role in treatment selection and association with clinical outcomes.
Hina Khan, Nagla Fawzy Abdel Karim(Augusta University), Girindra Raval(Augusta University), Hirva Mamdani(Wayne State University), B. Halmos(Albert Einstein College of Medicine), Ari M. Vanderwalde(West Cancer Center), Stephen V. Liu(Georgetown University), Milan Radovich(Caris Life Sciences (United States)), Matthew J. Oberley(Caris Life Sciences (United States)), Asad Ullah(Texas Tech University), C. Patrick(Penn State Milton S. Hershey Medical Center), Jorge J. Nieva(University of Southern California), Joanne Xiu(Caris Life Sciences (United States)), So Yeon Kim(Ulsan College), Hossein Borghaei(Fox Chase Cancer Center), Julia Judd(Palmetto Hematology Oncology), Luis E. Raez(Florida International University)
Cited by 2
Related Papers
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)
|Journal of Clinical Oncology|2021|818
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
|Journal of Thoracic Oncology|2018|661